Active immunotherapy in leukemia with neuraminidase-modified leukemic cells.
D000818:Animals; D000951:Antigens, Neoplasm; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D006801:Humans; D006968:Hypersensitivity, Delayed; D007114:Immunization; D007167:Immunotherapy; D009052:Leukemia Virus, Murine; D007942:Leukemia, Experimental / Q000517:prevention & control / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008806:Mice, Inbred AKR; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009439:Neuraminidase / Q000494:pharmacology*; D014412:Tumor Virus Infections / Q000628:therapy
D000951:Antigens, Neoplasm; D003561:Cytarabine; D009439:Neuraminidase; D003630:Daunorubicin